Numerous selective c-Met inhibitors have been developed (Figure 1), such as savolitinib (in clinical trials for renal cell carcinoma), capmatinib and tepotinib (authorized for MET exon 14-altered NSCLC), and crizotinib (initially an ALK/c-Met inhibitor, FDA-approved for NSCLC) [9]. This evidence concerns the gene MET and hereditary clear cell renal cell carcinoma.